Clinical testing of antiretroviral drugs as future prevention against vaginal and rectal transmission of HIV infection – a review of currently available results

1. M. Peeters, M. D’Arc and E. Delaporte, The origin and diversity of human retroviruses, AIDS Rev. 16 (2014) 23–34.Search in Google Scholar

2. World Health Organization, Progress Report 2016: Prevent HIV, Test and Treat All: WHO Support for Country Impact, WHO, 2016; http://www.who.int/iris/handle/10665/251713; last access date January 18, 2019.Search in Google Scholar

3. J. M. Excler and N. L. Michael, Lessons from HIV-1 vaccine efficacy trials, Curr. Opin. HIV AIDS11 (2016) 607–613; https://doi.org/10.1097/COH.000000000000031210.1097/COH.0000000000000312Search in Google Scholar

4. Z. A. Stein, Vaginal microbicides and prevention of HIV infection, Lancet343 (1994) 362–363; https://doi.org/10.1016/S0140-6736(94)91205-X10.1016/S0140-6736(94)91205-XSearch in Google Scholar

5. J. Balzarini and L. Van Damme, Microbicide drug candidates to prevent HIV infection, Lancet369 (2007) 787–797; https://doi.org/10.1016/S0140-6736(07)60202-510.1016/S0140-6736(07)60202-5Search in Google Scholar

6. L. M. Ferguson and L. C. Rohan, The importance of the vaginal delivery route for antiretrovirals in HIV prevention, Ther. Deliv.2 (2011) 1535–1550; https://doi.org/10.4155/tde.11.12610.4155/tde.11.126331433722468220Search in Google Scholar

7. Z. Si, N. Madani, J. M. Cox, J. J. Chruma, J. C. Klein, A. Schön, N. Phan, L. Wang, A. C. Biorn, S. Cocklin, I. Chaiken, E. Freire, A. B. Smith III and J. G. Sodroski, Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins, Proc. Natl. Acad. Sci. USA101 (2004) 5036–5041; https://doi.org/10.1073/pnas.030795310110.1073/pnas.030795310138736915051887Search in Google Scholar

8. L. D. Saravolatz and M. S. Saag, Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus, Clin. Infect. Dis.42 (2006) 126–131; https://doi.org/http://doi.org/10.1086/49834810.1086/49834816323102Search in Google Scholar

9. N. Ray, Maraviroc in the treatment of HIV infection, Drug Des. Devel. Ther.2 (2008) 151–161; https://doi.org/10.2147/DDDT.S347410.2147/DDDT.S3474276119219920903Search in Google Scholar

10. J. Kenney, M. Aravantinou, R. Singer, M. Hsu, A. Rodriguez, L. Kizima, C. J. Abraham, R. Menon, S. Seidor, A. Chudolij, A. Gettie, J. Blanchard, J. D. Lifson, M. Piatak Jr., J. A. Fernández-Romero, T. M. Zydowsky and M. Robbiani, Antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques, PLoS ONE6 (2011) e15835; https://doi.org/10.1371/journal.pone.001583510.1371/journal.pone.0015835301641321246052Search in Google Scholar

11. T. Bar-Magen, R. D. Sloan, D. A. Donahue, B. D. Kuhl, A. Zabeida, H. Xu, M. Oliveira, D. J. Hazuda and M. A. Wainberg, Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor, J. Virol.84 (2010) 9210–9216; https://doi.org/10.1128/JVI.01164-1010.1128/JVI.01164-10293759720610719Search in Google Scholar

12. A. S. Ray, M. W. Fordyce and M. J. Hitchcock, Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of human immunodeficiency virus, Antiviral Res.125 (2016) 63–70; https://doi.org/10.1016/j.antiviral.2015.11.00910.1016/j.antiviral.2015.11.00926640223Search in Google Scholar

13. B. P. Kearney, J. F. Flaherty and J. Shah, Tenofovir disoproxil fumarate clinical pharmacology and pharmacokinetics, Clin. Pharmacokinet.43 (2004) 595–616; https://doi.org/10.2165/00003088-200443090-0000310.2165/00003088-200443090-00003Search in Google Scholar

14. S. Di Fabio, J. Van Roey, G. Giannini, G. van den Mooter, M. Spada, A. Binelli, M. F. Pirillo, E. Germinario, F. Belardelli, M. P. de Bethune and S. Vella, Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation, AIDS17 (2003) 1597–1604; https://doi.org/10.1097/01.aids.0000072663.21517.63Search in Google Scholar

15. J. Balzarini, H. Pelemans, S. Aquaro, C. F. Perno, M. Witvrouw, D. Schols, E. De Clercq and A. Karlsson, Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication, Mol. Pharmacol. 50 (1996) 394–401.Search in Google Scholar

16. T. J. Wilkin, Z. Su, A. Krambrink, J. Long, W. Greaves, R. Gross, M. D. Hughes, C. Flexner, P. R. Skolnik, E. Coakley, C. Godfrey, M. Hirsch, D. R. Kuritzkes and R. M. Gulick, Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected, treatment-experienced patients, J. Acquir. Immune Defic. Syndr.5 (2010) 470–476; http://doi.org/10.1097/QAI.0b013e3181e2cba010.1097/QAI.0b013e3181e2cba0Search in Google Scholar

17. N. J. Alexander, E. Baker, M. Kaptein, U. Karc, L. Mille and E. Zampaglione, Why consider vaginal drug administration?, Fertil. Steril.82 (2004) 1–12; https://doi.org/10.1016/j.fertnstert.2004.01.02510.1016/j.fertnstert.2004.01.025Search in Google Scholar

18. D. R. Friend and P. F. Kiser, Assessment of topical microbicides to prevent HIV-1 transmission: Concepts, testing, lessons learned, Antiviral Res.99 (2013) 391–400; https://doi.org/10.1016/j.antiviral.2013.06.02110.1016/j.antiviral.2013.06.021Search in Google Scholar

19. D. J. Schaeffer and V. S. Krylov, Anti-HIV activity of extracts and compounds from algae and cyanobacteria, Ecotoxicol. Environ. Saf.45 (2000) 208–227; https://doi.org/10.1006/eesa.1999.186210.1006/eesa.1999.1862Search in Google Scholar

20. B. Cutler and J. Justman, Vaginal microbicides and the prevention of HIV transmission, Lancet Infect. Dis.8 (2008) 685–697; https://doi.org/10.1016/S1473-3099(08)70254-810.1016/S1473-3099(08)70254-8Search in Google Scholar

21. D. Huskens, K. Vermeire, A. T. Profy and D. Schols, The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1, Antiviral Res.84 (2009) 38–47; https://doi.org/10.1016/j.antiviral.2009.07.01310.1016/j.antiviral.2009.07.01319664662Search in Google Scholar

22. L. Van Damme, R. Govinden, F. M. Mirembe, F. Guédou, S. Solomon, M. L. Becker, B. S. Pradeep, A. K. Krishnan, M. Alary, B. Pande, G. Ramjee, J. Deese, T. Crucitti, D. Taylor and CS study group, Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission, N. Engl. J. Med.359 (2008) 463–472; https://doi.org/10.1056/NEJMoa070795710.1056/NEJMoa070795718669425Search in Google Scholar

23. D. Tyssen, S. A. Henderson, A. Johnson, J. Sterjovski, K. Moore, J. La, M. Zanin, S. Sonza, P. Karellas, M. P. Giannis, G. Krippner, S. Wesselingh, T. McCarthy, P. R. Gorry, P. A. Ramsland, R. Cone, J. R. Paull, G. R. Lewis and G. Tachedjian, Structure activity relationship of dendrimer microbicides with dual action antiviral activity, PLoS ONE5 (2010) e12309; https://doi.org/10.1371/journal.pone.001230910.1371/journal.pone.0012309292589320808791Search in Google Scholar

24. D. Serfaty, Contraception during perimenopause: The spermicides option, J. Gynecol. Obstet. Hum. Reprod. 46 (2017) 211–218; https://doi.org/10.1016/j.jogoh.2016.10.00710.1016/j.jogoh.2016.10.00728403917Search in Google Scholar

25. L. Van Damme, G. Ramjee, M. Alary, B. Vuylsteke, V. Chandeying, H. Rees, P. Sirivongrangson, L. Mukenge-Tshibaka, V. Ettiègne-Traoré, C. Uaheowitchai, S. S. Karim, B. Mâsse, J. Perriëns, M. Laga and COL-1492 study group, Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial, Lancet360 (2002) 971–977; https://doi.org/10.1016/S0140-6736(02)11079-810.1016/S0140-6736(02)11079-8Search in Google Scholar

26. J. Kreiss, E. Ngugi, K. Holmes, J. Ndinya-Achola, P. Waiyaki, P. L. Roberts, I. Ruminjo, R. Sajabi, J. Kimata, T. R. Fleming, A. Anzala, D. Holton and F. Plummer, Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes, JAMA268 (1992) 477–482; https://doi.org/10.1001/jama.1992.0349004005302510.1001/jama.1992.03490040053025Search in Google Scholar

27. R. E. Roddy, L. Zekeng, K. A. Ryan, U. Tamoufé, S. S. Weir and E. L. Wong, A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases, N. Engl. J. Med.339 (1998) 504–510; https://doi.org/10.1056/NEJM19980820339080310.1056/NEJM199808203390803Search in Google Scholar

28. D. Wilkinson, M. Tholandi, G. Ramjee and G. W. Rutherford, Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women, Lancet Infect. Dis. 2 (2002) 613–617; https://doi.org/10.1016/S1473-3099(02)00396-110.1016/S1473-3099(02)00396-1Search in Google Scholar

29. P. J. Feldblum, A. Adeiga, R. Bakare, S. Wevill, A. Lendvay, F. Obadaki, M. O. Olayemi, L. Wang, K. Nanda and W. Rountree, SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria, PLoS ONE3 (2008) e1474; https://doi.org/10.1371/journal.pone.000147410.1371/journal.pone.0001474Search in Google Scholar

30. S. Skoler-Karpoff, G. Ramjee, K. Ahmed, L. Altini, M. G. Plagianos, B. Friedland, S. Govender, A. De Kock, N. Cassim, T. Palanee, G. Dozier, R. Maguire and P. Lahteenmaki, Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial, Lancet372 (2008) 1977–1987; https://doi.org/10.1016/S0140-6736(08)61842-510.1016/S0140-6736(08)61842-5Search in Google Scholar

31. The Carraguard Phase II South Africa study team, Expanded safety and acceptability of the candidate vaginal microbicide Carraguard^® in South Africa, Contraception82 (2010) 563–571; https://doi.org/10.1016/j.contraception.2010.04.01910.1016/j.contraception.2010.04.019Search in Google Scholar

32. S. McCormack, G. Ramjee, A. Kamali, H. Rees, A. M. Crook, M. Gafos, U. Jentsch, R. Pool, M. Chisembele, S. Kapiga, R. Mutemwa, A. Vallely, T. Palanee, Y. Sookrajh, C. J. Lacey, J. Darbyshire, H. Grosskurth, A. Profy, A. Nunn, R. Hayes and J. Weber, PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides development programme 301): a phase 3, randomised, double-blind, parallel-group trial, Lancet376 (2010) 1329–1337; https://doi.org/10.1016/S0140-6736(10)61086-010.1016/S0140-6736(10)61086-0Search in Google Scholar

33. V. Pirrone, B. Wigdahl and F. C. Krebs, The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1, Antiviral. Res.90 (2011) 168–182; https://doi.org/10.1016/j.antiviral.2011.03.17610.1016/j.antiviral.2011.03.17621439325Search in Google Scholar

34. T. D. McCarthy, P. Karellas, S. A. Henderson, M. Giannis, D. F. O’Keefe, G. Heery, J. R. Paull, B. R. Matthews and G. Holan, Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention, Mol. Pharm. 2 (2005) 312–318; https://doi.org/10.1021/mp050023q10.1021/mp050023q16053334Search in Google Scholar

35. C. F. Price, D. Tyssen, S. Sonza, A. Davie, S. Evans, G. R. Lewis, S. Xia, T. Spelman, P. Hodsman, T. R. Moench, A. Humberstone, J. R. Paull and G. Tachedjian, SPL7013 Gel (VivaGel^®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans, PLoS ONE6 (2011) e24095; https://doi.org/10.1371/journal.pone.002409510.1371/journal.pone.0024095Search in Google Scholar

36. M. Hiorth, S.Nilsen and I. Tho, Bioadhesive mini-tablets for vaginal drug delivery, Pharmaceutics6 (2014) 494–511; https://doi.org/10.3390/pharmaceutics603049410.3390/pharmaceutics6030494Search in Google Scholar

37. C. Kempf, P. Jentsch, F. B. Barre-Sinoussi, B. Poirier, J. J. Morgenthaler, A. Morell and D. Germann, Inactivation of human immunodeficiency virus (HIV) by low pH and pepsin, J. Acquir. Immune Defic. Syndr. 4 (1991) 828–830.Search in Google Scholar

38. S. S. A. Karim, B. A. Richardson, G. Ramjee, I. F. Hoffman, Z. M. Chirenje, T. Taha, M. Kapina, L. Maslankowski, A. Coletti, A. Profy, T. R. Moench, E. Piwowar-Manning, B. Mâsse, S. L. Hillier, L. Soto-Torres and HIV prevention trials network (HPTN) 035 study team, Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women, AIDS25 (2011) 957–966; https://doi.org/10.1097/QAD.0b013e32834541d910.1097/QAD.0b013e32834541d9Search in Google Scholar

39. K. H. Mayer, L. A. Maslankowski, F. Gai, W. M. El-Sadr, J. Justman, A. Kwiecien, B. Mâsse, S. H. Eshleman, C. Hendrix, K. Morrow, J. F. Rooney, L. Soto-Torres and HPTN 050 protocol team, Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women, AIDS20 (2006) 543–451; https://doi.org/10.1097/01.aids.0000210608.70762.c310.1097/01.aids.0000210608.70762.c3Search in Google Scholar

40. Q. A. Karim, S. S. A. Karim, J. A. Frohlich, A. C. Grobler, C. Baxter, L. E. Mansoor, A. B. Kharsany, S. Sibeko, K. P. Mlisana, Z. Omar, T. N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, D. Taylor and CAPRISA 004 trial group, Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women, Science329 (2010) 1168–1174; https://doi.org/10.1126/science.119374810.1126/science.1193748Search in Google Scholar

41. A. D. Kashuba, T. N. Gengiah, L. Werner, K. H. Yang, N. R. White, Q. A. Karim and S. S. A. Karim, Genital tenofovir concentrations correlate with protection against HIV infection in the CAPRISA 004 trial: Importance of adherence for microbicide effectiveness, J. Acquir. Immune Defic. Syndr. 69 (2015) 264–269; https://doi.org/10.1097/QAI.000000000000060710.1097/QAI.0000000000000607Search in Google Scholar

42. J. M. Marrazzo, G. Ramjee, B. A. Richardson, K. Gomez, N. Mgodi, G. Nair, T. Palanee, C. Nakabiito, A. van der Straten, L. Noguchi, C. W. Hendrix, J. Y. Dai, S. Ganesh, B. Mkhize, M. Taljaard, U. M. Parikh, J. Piper, B. Mâsse, C. Grossman, J. Rooney, J. L. Schwartz, H. Watts, M. A. Marzinke, S. L. Hillier, I. M. McGowan, Z. M. Chirenje and VOICE study team, Tenofovir-based preexposure prophylaxis for HIV infection among African women, N. Engl. J. Med. 372 (2015) 509–518; https://doi.org/10.1056/NEJMoa140226910.1056/NEJMoa1402269Search in Google Scholar

43. Q. A. Karim, C. Baxter and S. A. Karim, Microbicides and their potential as a catalyst for multi-purpose sexual and reproductive health technologies, BJOG12 (2014) 53–61; https://doi.org/10.1111/1471-0528.1284310.1111/1471-0528.12843Search in Google Scholar

44. H. Rees, S. A. Delany-Moretlwe, C. Lombard, D. Baron, R. Panchia, L. Myer, J. L. Schwartz, G. F. Doncel and G. Gray, FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women, in Conference on Retroviruses and Opportunistic Infections, February 23-26, 2015, Seattle, Washington, abstract no. 26LB; https://www.croiconference.org/sessions/facts-001-phase-iii-trial-pericoital-tenofovir-1-gel-hiv-prevention-women; last access date January 18, 2019.10.1016/S1473-3099(18)30428-6Search in Google Scholar

45. L. E. Mansoor, Q. A. Karim, K. T. Mngadi, S. Dlamini, C. Montague, N. Nkomonde, N. Mvandaba, C. Baxter, T. N. Gengiah, N. Samsunder, H. Dawood, A. Grobler, J. A. Frohlich and S. S. A. Karim, Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial, Trials15 (2014) Article ID 496 (9 pages); https://doi.org/10.1186/1745-6215-15-49610.1186/1745-6215-15-496430082825527071Search in Google Scholar

46. K. M. MacQueen, S. Dlamini, B. Perry, E. Okumu, S. Sortijas, C. Singh, D. Pillay, A. Majors, S. Jerome, S. Watson, S. A. Karim, Q. A. Karim and L. E. Mansoor, Social context of adherence in an open-label 1% tenofovir gel trial: gender dynamics and disclosure in KwaZulu-Natal, South Africa, AIDS Behav. 20 (2016) 2682–2691; https://doi.org/10.1007/s10461-016-1339-410.1007/s10461-016-1339-4506932726945585Search in Google Scholar

47. J. Cohen, Infectious disease. Vaginal microbiome affects HIV risk, Science353 (2016) 331; https://doi.org/10.1126/science.353.6297.33110.1126/science.353.6297.33127463647Search in Google Scholar

48. N. R. Klatt, R. Cheu, K. Birse, A. S. Zevin, M. Perner, L. Noël-Romas, A. Grobler, G. Westmacott, I. Y. Xie, J. Butler, L. Mansoor, L. R. McKinnon, J. S. Passmore, Q. A. Karim, S. S. A. Karim and A. D. Burgener, Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women, Science356 (2017) 938–945; https://doi.org/10.1126/science.aai938310.1126/science.aai938328572388Search in Google Scholar

49. A. M. Nel, P. Coplan, J. H. van de Wijgert, S. H. Kapiga, C. von Mollendorf, E. Geubbels, J. Vyankandondera, H. V. Rees, G. Masenga, I. Kiwelu, J. Moyes and S. C. Smythe, Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women, AIDS23 (2009) 1531–1538; https://doi.org/10.1097/QAD.0b013e32832c413d10.1097/QAD.0b013e32832c413d19550287Search in Google Scholar

50. A. M. Nel, S. C. Smythe, S. Habibi, P. E. Kaptur and J. W. Romano, Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel, J. Acquir. Immune Defic. Syndr.55 (2010) 161–169; https://doi.org/10.1097/QAI.0b013e3181e3293a10.1097/QAI.0b013e3181e3293a20574411Search in Google Scholar

51. B. Devlin, J. Nuttall, S. Wilder, C. Woodsong and Z. Rosenberg, Development of dapivirine vaginal ring for HIV prevention, Antiviral Res.100 (2013) S3–S8; https://doi.org/10.1016/j.antiviral.2013.09.02510.1016/j.antiviral.2013.09.02524188702Search in Google Scholar

52. R. K. Malcolm, P. J. Boyd, C. F. McCoy and D. J. Murphy, Microbicide vaginal rings: Technological challenges and clinical development, Adv Drug Deliv Rev.103 (2016) 33–56; https://doi.org/10.1016/j.addr.2016.01.01510.1016/j.addr.2016.01.01526829289Search in Google Scholar

53. A. Nel, L. G. Bekker, E. Bukusi, E. Hellstrӧm, P. Kotze, C. Louw, F. Martinson, G. Masenga, E. Montgomery, N. Ndaba, A. van der Straten, N. van Niekerk and C. Woodsong, Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in Sub-Saharan Africa, PLoS ONE11 (2016) e0147743; https://doi.org/10.1371/journal.pone.014774310.1371/journal.pone.0147743478633626963505Search in Google Scholar

54. J. M. Baeten, T. Palanee-Phillips, E. R. Brown, K. Schwartz, L. E. Soto-Torres, V. Govender, N. M. Mgodi, F. Matovu Kiweewa, G. Nair, F. Mhlanga, S. Siva, L. G. Bekker, N. Jeenarain, Z. Gaffoor, F. Martinson, B. Makanani, A. Pather, L. Naidoo, M. Husnik, B. A. Richardson, U. M. Parikh, J. W. Mellors, M. A. Marzinke, C. W. Hendrix, A. van der Straten, G. Ramjee, Z. M. Chirenje, C. Nakabiito, T. E. Taha, J. Jones, A. Mayo, R. Scheckter, J. Berthiaume, E. Livant, C. Jacobson, P. Ndase, R. White, K. Patterson, D. Germuga, B. Galaska, K. Bunge, D. Singh, D. W. Szydlo, E. T. Montgomery, B. S. Mensch, K. Torjesen, C. I. Grossman, N. Chakhtoura, A. Nel, Z. Rosenberg, I. McGowan, S. Hillier, and MTN-020–ASPIRE study team, Use of a vaginal ring containing dapivirine for HIV-1 prevention in women, N. Engl. J. Med.375 (2016) 2121–2132; https://doi.org/10.1056/NEJMoa150611010.1056/NEJMoa1506110499369326900902Search in Google Scholar

55. A. Nel, N. van Niekerk, S. Kapiga, L. G. Bekker, C. Gama, K. Gill, A. Kamali, P. Kotze, C. Louw, Z. Mabude, N. Miti, S. Kusemererwa, H. Tempelman, H. Carstens, B. Devlin, M. Isaacs, M. Malherbe, W. Mans, J. Nuttall, M. Russell, S. Ntshele, M. Smit, L. Solai, P. Spence, J. Steytler, K. Windle, M. Borremans, S. Resseler, J. Van Roey, W. Parys, T. Vangeneugden, B. Van Baelen, Z. Rosenberg and Ring study team, Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women, N. Engl. J. Med. 375 (2016) 2133–2143; https://doi.org/10.1056/NEJMoa160204610.1056/NEJMoa160204627959766Search in Google Scholar

56. A. Nel, W. Haazen, M. Russell, J. Nuttall, N. Van Niekerk and N. Treijtel, Drug-drug interactions between the dapivirine vaginal ring (Ring-004) and miconazole nitrate vaginal capsule (Gyno-Daktarin^®), AIDS Res. Hum. Retroviruses30 (2014) A144. https://doi.org/10.1089/aid.2014.5291.abstract10.1089/aid.2014.5291.abstractSearch in Google Scholar

57. To assess the drug-drug interaction potential between dapivirine vaginal ring-004, containing 25 mg of dapivirine, and clotrimazole 10 mg/g (1%); https://clinicaltrials.gov/ct2/show/record/NCT02847286; last access date January 18, 2019.Search in Google Scholar

58. V. Jespers, C. Noestlinger and K. K. Ariën, Designing microbicides against HIV: innovative rings for young women urgently needed, Future Virol. 12 (2017) 45–48; https://doi.org/10.2217/fvl-2016-013510.2217/fvl-2016-0135Search in Google Scholar

59. K. Bunge, L. Levy, D. Szydlo, J. Zhang, A. Gaur, D. Reirden, K. Mayer, D. Futterman, C. Hoesley, S. Hillier, M. Marzinke, C. Dezzutti, C. Wilson, L. Soto-Torres, B. Kapogiannis, A. Nel, K. Squires, and MTN-023/IPM 030 protocol team, Safety and acceptability trial of the dapivirine vaginal ring in U.S. adolescents, The 9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris (France); http://programme.ias2017.org/Abstract/Abstract/5540; last access date January 27, 2019.Search in Google Scholar

60. L. Noguchi, R. Beigi, J. Biggio, M. Marzinke, C. Kelly, K. Bunge, R. Scheckter, J. Piper, S. Hillier, A. Nel and C. Hendrix, Breast milk dapivirine pharmacokinetics, estimated infant exposure, and safety during dapivirine intravaginal ring use among lactating women, Am. J. Obstet. Gynecol. 217 (2017) 717–717; https://doi.org/10.1016/j.ajog.2017.08.08910.1016/j.ajog.2017.08.089Search in Google Scholar

61. P. Spence, A. Nel, N. van Niekerk, T. Derrick, S. Wilder and B. Devlin, Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence, J. Pharm. Biomed. Anal.125 (2016) 94–100; https://doi.org/10.1016/j.jpba.2016.03.02310.1016/j.jpba.2016.03.023487360127016673Search in Google Scholar

62. Trial to assess the continued safety of and adherence to a vaginal ring containing dapivirine in women; https://clinicaltrials.gov/ct2/show/record/NCT02858037?term=MTN-025&rank=1&view=record; last access date January 27, 2019.Search in Google Scholar

63. To assess continued safety of and adherence to the dapivirine (25 mg) vaginal ring-004 in healthy, HIV-negative Women; https://clinicaltrials.gov/ct2/show/NCT02862171?term=IPM+032&rank=1; last access date January 27, 2019.Search in Google Scholar

64. J. Baeten and C. Celum, HIV Prevention at CROI 2018 and PrEP updates on PrEP - disparities; current & future; delivery/use/barriers; women, transmission clusters, Conference on Retroviruses and Opportunistic Infections, Boston (MA), USA, March 4–7, 2018; http://www.natap.org/2018/CROI/croi_188.htm; last access date January 27, 2019.Search in Google Scholar

65. R. K. Malcolm, K. L. Edwards, P. Kiser, J. Romano and T. J. Smith, Advances in microbicide vaginal rings, Antiviral Res.88 (2010) S30–S39; https://doi.org/10.1016/j.antiviral.2010.09.00310.1016/j.antiviral.2010.09.00321109066Search in Google Scholar

66. The quatro study: Acceptability study of (placebo) vaginal delivery forms for preventing HIV and unintended pregnancy; https://clinicaltrials.gov/ct2/show/NCT02602366; last access date January 18, 2019.Search in Google Scholar

67. T. A. Jacot, M. R. Clark, O. E. Adedipe, S. Godbout, A. G. Peele, S Ju, J. L. Schwartz, A. R. Thurman and G. F. Doncel, Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies, Clin. Transl. Med.7 (2018) 37–37; https://doi.org/10.1186/s40169-018-0213-610.1186/s40169-018-0213-6621999830402770Search in Google Scholar

68. K. E. Bunge, C. S. Dezzutti, L. C. Rohan, C. W. Hendrix, M. A. Marzinke, N. Richardson-Harman, B. J. Moncla, B. Devlin, L. A. Meyn, H. M. Spiegel and S. L. Hillier, A phase 1 trial to assess the safety, acceptability, pharmacokinetics, and pharmacodynamics of a novel dapivirine vaginal film, J. Acquir. Immune Defic. Syndr.71 (2016) 498–505; https://doi.org/10.1097/QAI.000000000000089710.1097/QAI.0000000000000897504083026565716Search in Google Scholar

69. J. A. Robinson, M. A. Marzinke, R. P. Bakshi, E. J. Fuchs, C. L. Radebaugh, W. Aung, H. M. Spiegel, J. S. Coleman, L. C. Rohan and C. W. Hendrix, Comparison of dapivirine vaginal gel and film formulation pharmacokinetics and pharmacodynamics (FAME 02B), AIDS Res. Hum. Retroviruses33 (2017) 339–346; https://doi.org/10.1089/AID.2016.004010.1089/aid.2016.0040Search in Google Scholar

70. H. Agashe, M. Hu and L. Rohan, Formulation and delivery of microbicides, Curr. HIV Res.10 (2012) 88–96; https://doi.org/10.2174/15701621279930459910.2174/15701621279930459922264050Search in Google Scholar

71. Study of UC-781 vaginal microbicide; https://clinicaltrials.gov/ct2/show/record/NCT00132444?term=NCT00132444&rank=1; last access date January 18, 2019.Search in Google Scholar

72. Phase I study of safety and persistence of UC-781 vaginal microbicide; https://clinicaltrials.gov/ct2/show/NCT00441909?term=NCT00441909&rank=1; last access date January 21, 2019.Search in Google Scholar

73. K. Bunge, I. Macio, L. Meyn, L. Noguchi, M. A. Parniak, J. L. Schwartz, B. Moncla and S. Hillier, The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781, J. Acquir. Immune Defic. Syndr.60 (2012) 337–343; https://doi.org/10.1097/QAI.0b013e318257591410.1097/QAI.0b013e318257591422495787Search in Google Scholar

74. Safety study of UC-781 vaginal microbicide; https://clinicaltrials.gov/ct2/show/NCT00446979?term=NCT00446979&rank=1; last access date January 21, 2019.Search in Google Scholar

75. R. E. Haaland, T. Evans-Strickfaden, A. Holder, C. P. Pau, J. M. McNicholl, C. Chaikummao, W. Chonwattana and C. E. Hart, UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application, Antimicrob. Agents Chemother.56 (2012) 3592–3596; https://doi.org/10.1128/AAC.00452-1210.1128/AAC.00452-12339339822508307Search in Google Scholar

76. M. J. Keller, P. M. Mesquita, M. A. Marzinke, R. Teller, L. Espinoza, J. M. Atrio, Y. Lo, B. Frank, S. Srinivasan, D. N. Fredricks, L. Rabe, P. L. Anderson, C. W. Hendrix, P. F. Kiser and B. C. Herold, A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring, AIDS30 (2016) 743–751; https://doi.org/10.1097/QAD.000000000000097910.1097/QAD.0000000000000979476757926605514Search in Google Scholar

77. O. Mizenina, M. Hsu, N. Jean-Pierre, M. Aravantinou, K. Levendosky, G. Paglini, T. M. Zydowsky, M. Robbiani and J. A. Fernández-Romero, MIV-150 and zinc acetate combination provides potent and broad activity against HIV-1, Drug Deliv. Transl. Res.7 (2017) 859–866; https://doi.org/10.1007/s13346-017-0421-410.1007/s13346-017-0421-428812250Search in Google Scholar

78. B. A. Friedland, C. J. Hoesley, M. Plagianos, E. Hoskin, S. Zhang, N. Teleshova, M. Alami, L. Novak, K. R. Kleinbeck, L. L. Katzen, T. M. Zydowsky, J. A. Fernández-Romero and G. W. Creasy, First-in-human trial of MIV-150 and zinc acetate coformulated in a carrageenan gel: safety, pharmacokinetics, acceptability, adherence, and pharmacodynamics, J. Acquir. Immune Defic. Syndr. 73 (2016) 489–496; https://doi.org/10.1097/QAI.000000000000113610.1097/QAI.0000000000001136517284827437826Search in Google Scholar

79. Evaluate the safety and assess local and systemic PK of DS003 vaginal tablets administered to healthy HIV-negative women; https://clinicaltrials.gov/ct2/show/NCT02877979?term=IPM+042&rank=1; last access date January 21, 2019.Search in Google Scholar

80. S. M. Fetherston, P. Boyd, C. F. McCoy, M. C. McBride, K. L. Edwards, S. Ampofo and R. K. Malcolm, A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action, Eur. J. Pharm. Sci.48 (2013) 406–415; https://doi.org/10.1016/j.ejps.2012.12.00210.1016/j.ejps.2012.12.00223266465Search in Google Scholar

81. M. R. Clark, M. M. Peet, S. Davis, G. F. Doncel and D. R. Friend, Evaluation of rapidly disintegrating vaginal tablets of tenofovir, emtricitabine and their combination for HIV-1 prevention, Pharmaceutics6 (2014) 616–631; https://doi.org/10.3390/pharmaceutics604061610.3390/pharmaceutics6040616427913625494201Search in Google Scholar

82. Safety, pharmacokinetics, pharmacodynamics, and disintegration time of vaginal tablets containing tenofovir and/or emtricitabine; https://clinicaltrials.gov/ct2/show/study/NCT01694407?term=emtricitabine+vaginal&rank=2; last access date January 27, 2019.Search in Google Scholar

83. B. A. Chen, L. Panther, M. A. Marzinke, C. W. Hendrix, C. J. Hoesley, A. van der Straten, M. J. Husnik, L. Soto-Torres, A. Nel, S. Johnson, N. Richardson-Harman, L. K. Rabe and C. S. Dezzutti, Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: a double-blind randomized trial, J. Acquir. Immune Defic. Syndr.70 (2015) 242–249; https://doi.org/10.1097/QAI.000000000000070210.1097/QAI.0000000000000702460758726034880Search in Google Scholar

84. Safety and pharmacokinetics of intravaginal rings containing vicriviroc (MK-4176) and/or MK-2048; https://clinicaltrials.gov/ct2/show/NCT02356302?term=MTN-027&rank=1; last access date January 21, 2019.Search in Google Scholar

85. C. J. Hoesley, B. A. Chen, P. L. Anderson, C. S. Dezzutti, J. Strizki, C. Sprinkle, F. Heard, J. Bauermeister, W. Hall, C. Jacobson, J. Berthiaume, A. Mayo, H. Gundacker, N. Richardson-Harman and J. Piper, Microbicide Trials Network 027 Study Team, Phase 1 safety and pharmacokinetics study of MK-2048/vicriviroc (MK-4176)/MK-2048A intravaginal rings, Clin. Infect. Dis., Oct 2018 (in press); https://doi.org/10.1093/cid/ciy65310.1093/cid/ciy653642407530289435Search in Google Scholar

86. Safety and pharmacokinetic study of hiv prophylaxis using antiretroviral intravaginal rings in healthy women; https://clinicaltrials.gov/ct2/show/NCT02431273?term=NCT02431273&rank=1; last access date January 27, 2019.Search in Google Scholar

87. K. L. Vincent, J. A. Moss, M. A. Marzinke, C. W. Hendrix, P. A. Anton, R. B. Pyles, K. M. Guthrie, L. Dawson, T. J. Olive, I. Butkyavichene, S. A. Churchman, J. M. Cortez Jr, R. Fanter, M. Gunawardana, C. S. Miller, F. Yang, R. K. Rosen, S. E. Vargas and M. M. Baum, Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A phase I trial, PLOS Med.15 (2018) e1002655; https://doi.org/10.1371/journal.pmed.100265510.1371/journal.pmed.1002655616185230265679Search in Google Scholar

88. R. Sitruk-Ware, A. Nath and D. R. Mishell, Jr., Contraception technology: past, present and future. Contraception87 (2013) 319–330; https://doi.org/10.1016/j.contraception.2012.08.00210.1016/j.contraception.2012.08.002353062722995540Search in Google Scholar

89. J. T. Clark, M. R. Clark, N. B. Shelke, T. J. Johnson, E. M. Smith, A. K. Andreasen, J. S. Nebeker, J. Fabian, D. R. Friend and P. F. Kiser, Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy, PLoS ONE9 (2014) e88509; https://doi.org/10.1371/journal.pone.008850910.1371/journal.pone.0088509394371824599325Search in Google Scholar

90. A. R. Thurman, J. L. Schwartz, V. Brache, M. R. Clark, T. McCormick, N. Chandra, M. A. Marzinke, F. Z. Stanczyk, C. S. Dezzutti, S. L. Hillier, B. C. Herold, R. Fichorova, S. N. Asin, C. Rollenhagen, D. Weiner, P. Kiser and G. F. Doncel, Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women, PLOS ONE13 e0199778; https://doi.org/10.1371/journal.pone.019977810.1371/journal.pone.0199778602323829953547Search in Google Scholar

91. PK and safety study of vaginal rings containing dapivirine and levonorgestrel (DAP/LNG); https://clinicaltrials.gov/ct2/show/NCT02855346?term=MTN-030%2FIPM+041&rank=1; last access date January 21, 2019.Search in Google Scholar

92. R. D. Cranston, J. R. Lama, B. A. Richardson, A. Carballo-Diéguez, R. P. Kunjara Na Ayudhya, K. Liu, K. B. Patterson, C. S. Leu, B. Galaska, C. E. Jacobson, U. M. Parikh, M. A. Marzinke, C. W. Hendrix, S. Johnson, J. M. Piper, C. Grossman, K. S. Ho, J. Lucas, J. Pickett, L. G. Bekker, S. Chariyalertsak, A. Chitwarakorn, P. Gonzales, T. H. Holtz, A. Y. Liu, K. H. Mayer, C. Zorrilla, J. L. Schwartz, J. Rooney, I. McGowan and MTN-017 protocol team, A rectal phase 2 extended safety and acceptability study of tenofovir reduced-glycerin 1% gel, Clin. Infect. Dis. 64 (2017) 614–620; https://doi.org/10.1093/cid/ciw83210.1093/cid/ciw832585051827986684Search in Google Scholar

93. A. Carballo-Diéguez, I. C. Balán, W. Brown, R. Giguere, C. Dolezal, C. Leu, M. A. Marzinke, C. W. Hendrix, J. M. Piper, B. A. Richardson, C.Grossman, S. Johnson, K. Gomez, S. Horn, R. P. K. Na Ayudhya, K. Patterson, C. Jacobson, L. Bekker, S. Chariyalertsak, A. Chitwarakorn, P. Gonzales, T. H. Holtz, A. Liu, K. H. Mayer, C. Zorrilla, J. Lama, I. McGowan and R. D. Cranston, High levels of adherence to a rectal microbicide gel and to oral pre-exposure prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women, PLOS ONE12 e0181607; https://doi.org/10.1371/journal.pone.018160710.1371/journal.pone.0181607553150328750059Search in Google Scholar

94. P. A. Anton, T. Saunders, J. Elliott, E. Khanukhova, R. Dennis, A. Adler, G. Cortina, K. Tanner, J. Boscardin, W. G. Cumberland, Y. Zhou, A. Ventuneac, A. Carballo-Diéguez, L. Rabe, T. McCormick, H. Gabelnick, C. Mauck and I. McGowan, First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy, PLoS ONE6 (2011) e23243; https://doi.org/10.1371/journal.pone.002324310.1371/journal.pone.0023243318216021969851Search in Google Scholar

95. Safety and pharmacokinetic study of oral maraviroc and maraviroc 1% gel in HIV-1 seronegative adults; https://clinicaltrials.gov/ct2/show/NCT02346084?term=NCT02346084&rank=1; last access date January 21, 2019.Search in Google Scholar